Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients
Portfolio Pulse from Benzinga Newsdesk
Fennec Pharmaceuticals has received marketing authorization from the European Commission for Pedmarqsi, the first and only approved therapy in the EU for preventing hearing loss in pediatric oncology patients aged 1 month to <18 years. Pedmarqsi was granted authorization under the paediatric-use marketing authorization (PUMA), which includes 8 years plus 2 years of data and market protection.

June 06, 2023 | 9:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Fennec Pharmaceuticals has received EU marketing authorization for Pedmarqsi, a therapy for preventing hearing loss in pediatric oncology patients, which could boost the company's revenue.
The European Commission's marketing authorization for Pedmarqsi allows Fennec Pharmaceuticals to market and sell the product in the EU. This is the first and only approved therapy for preventing hearing loss in pediatric oncology patients in the region, which could lead to increased demand and revenue for the company. The authorization also comes with 8 years plus 2 years of data and market protection, providing Fennec with a competitive advantage in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100